All analyses
AI analysis

Nawaloka Hospitals Plc: research report

Moderately overvaluedbearishOct 20, 2026

The evidence points bearish because June net profit fell 90.3% while the shares sit in the exchange's overvalued band. The offset is operating profit growth of 26.5%.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • It scores 16 of 100 on price against book value, earnings and dividends, placing it in the CSE's Overvalued band.
  • June-quarter net profit fell 90.3% year-on-year despite 19.4% revenue growth, showing that stronger hospital activity did not translate into shareholder earnings.
  • Debt was 111.8% of owners' equity at March 2026, while operating profit covered interest only 1.73 times.

Against this. June operating profit rose 26.5% year-on-year and gross margin was among the best June readings on record.

Operating margin
16.9%
from 17.3% a year earlier
Net margin
7.0%sector 13.0%
from 8.3% a year earlier, revenue +8.9%
Return on equity
16.3%sector 11.2%
full year to Mar 31, 2026
P/E
15.9sector 11.8
earnings Rs 0.75 per share, year to Mar 2026
P/B
2.46sector 1.36
book Rs 4.84 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 20, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Nawaloka Hospitals provides private inpatient, outpatient, diagnostic and specialist clinical services, alongside digital-health and international-patient offerings. The central change is a divergence in the latest quarter: core hospital operations improved, but finance costs, tax and other non-operating charges absorbed most of that improvement before it reached net profit.

Price performance

At LKR 10.20 on 20 October 2026, the share had fallen 15.6% over one month against a 4.7% fall in the ASPI. It sits near the bottom of its own 52-week range; recent volatility was below its own one-year norm, while 20-day volume was above its 60-day norm.

The share's record since February 2024 is five falls of 15% or more in three years, the deepest 41%, which has not yet recovered. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day (155% of it), making that order a large part of normal daily trading.

Valuation

At 13.6 times P/E, the market pays LKR 13.60 for every LKR 1 of trailing profit, above the healthcare peer median; the 2.37 times P/B means LKR 2.37 for each LKR 1 of net assets, also above the sector median. ROE was 16.3% for the year ended March 2026, which supports some premium to book, but not the absence of a dividend: no dividend is on record in the last two years.

Against its own record, the P/B is more expensive than 84% of days since February 2012. A buyer at this price is relying on a latest quarter that supplied only 10.7% of trailing EPS; if that quarter had retained its year-ago net margin, the same price would equate to 6.1 times earnings.

News and sentiment

Direct coverage is thin, with one material article in the past 90 days. An article reported on 19 October that Nawaloka increased its Digital Health, or Doc990, stake to 12.12% as Sunshine Healthcare acquired a holding, valuing Digital Health at LKR 1.87 billion; the report gives no terms showing a near-term earnings contribution to Nawaloka.

Financials

June-quarter revenue rose 19.4% and operating profit rose 26.5% year-on-year, but net profit fell 90.3%. Gross margin improved to 56.4% from 53.7%, operating margin to 14.5% from 13.7%, while net margin fell to 2.0% from 24.8%. Gross margin was the second-best June result in eight comparable June quarters, whereas operating and net margins ranked fourth and fifth respectively, so the operating improvement was solid but the conversion into bottom-line profit was ordinary for this period.

A LKR 440 million gap between operating and net profit, compared with a LKR 330 million contribution below operating profit a year earlier, explains the divergence. Costs, tax and other items below operating profit took most of the quarter's earnings.

Equity fell to LKR 6.1 billion from LKR 6.4 billion a year earlier, while the share count remained 1.409 billion. There was therefore no share-count change masking the deterioration in quarterly EPS.

Risks

The largest risk is funding pressure. At March 2026, debt was 111.8% of owners' equity and operating profit covered the interest bill only 1.73 times, leaving limited room if borrowing costs or operating profit move adversely.

The current ratio was 0.62, meaning the group had 62 cents of short-term assets, including receivables and inventories, for each LKR 1 of bills due within a year. Cash conversion was 0.44 times, so less than half of operating profit arrived as operating cash in the latest audited year; this matters when capital spending and debt service compete for cash.

Healthcare-sector conditions also include household pressure: essentials, including healthcare, accounted for 58% of spending in a cited sector study. That backdrop may constrain discretionary private-care demand, although it is not company-specific evidence.

Outlook

As at 20 October 2026, the next specific event is the September 2026 interim filing, expected between 6 and 14 November. It will show whether the June gap between operating profit and net profit persisted, and will supersede the current June-based assessment.

The available data cannot establish whether the expanded Doc990 holding will contribute meaningful earnings, because the reported transaction terms do not quantify Nawaloka's investment or earnings share. Higher bond yields and a weaker rupee in the broader market add a less favourable financing backdrop while debt remains elevated.

About this report. Generated on Oct 20, 2026 from market data up to Oct 20, 2026, 1 material news articles over 90 days and financials to Jun 30, 2026, and scored 16 of 100 on value (overvalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports